Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Privium Fund Management B.V.

Key Points

• Privium Fund Management B.V. increased its stake in Arrowhead Pharmaceuticals by 65.3%, now owning 629,214 shares, which represents 2.1% of its investment portfolio.
• Arrowhead Pharmaceuticals recently reported a quarterly earnings per share of $2.75, far exceeding analyst expectations of a loss of $0.06, with revenues of $542.71 million.
• Several analysts have given Arrowhead Pharmaceuticals a consensus rating of "Moderate Buy" with a target price averaging $43.71.

Privium Fund Management B.V. lifted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 65.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 629,214 shares of the biotechnology company's stock after buying an additional 248,628 shares during the quarter. Arrowhead Pharmaceuticals makes up about 2.1% of Privium Fund Management B.V.'s holdings, making the stock its 9th biggest holding. Privium Fund Management B.V. owned 0.46% of Arrowhead Pharmaceuticals worth $8,016,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Avoro Capital Advisors LLC lifted its stake in Arrowhead Pharmaceuticals by 25.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock valued at $208,889,000 after acquiring an additional 2,222,223 shares during the period. Slate Path Capital LP lifted its stake in shares of Arrowhead Pharmaceuticals by 7.1% in the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock worth $98,362,000 after purchasing an additional 347,000 shares during the period. Norges Bank bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $38,622,000. Northern Trust Corp raised its stake in Arrowhead Pharmaceuticals by 11.4% during the 4th quarter. Northern Trust Corp now owns 1,484,419 shares of the biotechnology company's stock worth $27,907,000 after acquiring an additional 151,654 shares during the period. Finally, Millennium Management LLC raised its stake in Arrowhead Pharmaceuticals by 41.7% during the 4th quarter. Millennium Management LLC now owns 914,550 shares of the biotechnology company's stock worth $17,194,000 after acquiring an additional 268,946 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Trading Down 1.1%

Arrowhead Pharmaceuticals stock traded down $0.18 during trading on Wednesday, hitting $16.29. The company's stock had a trading volume of 1,164,935 shares, compared to its average volume of 1,881,795. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.15 and a current ratio of 5.15. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $27.34. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -11.66, a P/E/G ratio of 19.36 and a beta of 0.94. The stock's fifty day moving average is $16.48 and its 200 day moving average is $16.04.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to the consensus estimate of $116.27 million. During the same period in the prior year, the business earned ($1.02) EPS. As a group, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Ratings Changes

ARWR has been the subject of several research reports. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.71.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.